HONG KONG, Oct. 2, 2026 /PRNewswire/ — A crypto miner using NiceHash EasyMining found two Bitcoin blocks on the same day in September without owning or operating mining hardware.

Bitcoin blocks #967911 and #967915 were found only four blocks apart and generated more than 6 BTC in combined block rewards. The miner had purchased Gold L Solo Mining packages through NiceHash EasyMining, at a cost of approximately 0.01 BTC per package.

The two discoveries highlight how EasyMining enables users to participate in mining by purchasing hashpower rather than buying and setting up their own equipment. Finding a block is uncertain, and purchasing a package does not guarantee a reward.

How EasyMining Works

NiceHash has operated a marketplace for computing power, known as hashpower, for more than a decade. EasyMining gives users a way to purchase a mining package and use its hashpower for a mining attempt.

Users select a package without having to buy an ASIC, install mining hardware at home or manage the technical setup themselves. The mining equipment is still operated by third parties; EasyMining users do not need to own or operate it.

Selected Packages Start at 5 USDT

Selected Bitcoin and Bitcoin Cash solo mining packages are available from 5 USDT. Users can choose an eligible package, pay with USDT and follow the outcome of the mining attempt through the platform. Package availability and pricing may vary.

EasyMining Presented in Hong Kong

NiceHash recently presented EasyMining at Bitcoin Asia in Hong Kong, where the company showcased its mining products to the Asian Bitcoin and crypto community.

Mining Options Beyond Bitcoin

Depending on the packages available, EasyMining supports mining attempts for proof-of-work cryptocurrencies including Bitcoin (BTC), Bitcoin Cash (BCH), Litecoin (LTC), Dogecoin (DOGE), Zcash (ZEC) and Kaspa (KAS).

Selected Bitcoin and Bitcoin Cash packages can be purchased with USDT, while other available EasyMining packages can be purchased with BTC.

Solo and Team Mining

EasyMining offers solo and team mining options. In solo mining, a user purchases a package whose hashpower attempts to find a block. The miner who found the two Bitcoin blocks was using solo mining packages.

In team mining, users purchase shares in a package and participate together. If the team finds a block, the reward is distributed according to participants’ shares and the applicable package rules.

By providing access to hashpower through mining packages, EasyMining allows users to try mining without purchasing equipment or managing a home mining setup.

More information is available at NiceHash EasyMining.

Easy Mining Website: https://www.nicehash.com/easymining?utm_campaign=easymining_launch_2026&utm_source=article_sea&utm_medium=paid_social&utm_content=article_sea&utm_id=south_asia&reffid=south_asia 

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/crypto-miner-found-two-bitcoin-blocks-in-one-day-with-rented-hashpower-via-nicehash—you-can-try-it-from-5-usdt-302897079.html

SOURCE NiceHash

HANOI, Vietnam, Oct. 2, 2026 /PRNewswire/ — On the occasion of Vietnam National Innovation Day (October 1) and Vietnam Encouragement of Learning Day (October 2), The 1st Vietnam Embodied AI Conference (AGIBOT Partner Conference) was held on October 2 in Hanoi. The conference was co-hosted by NIC, AGIBOT, and its Vietnamese partners ECOLIV and Great Education, attracting over 550 participants, including representatives from government agencies such as NIC, the Ministry of Science and Technology, the Ministry of Education and Training, and the Ministry of Industry and Commerce; senior representatives including principals from over 50 schools; representatives from more than 20 research institutions; as well as industry partners and end customers in the research, education, and industry sectors. The conference focused on cutting-edge embodied intelligence technologies, industrial applications, talent development, and ecosystem deployment, marking a significant step forward in AGIBOT’s embodied intelligence market expansion in Vietnam.

At the conference, AGIBOT showcased a comprehensive range of embodied intelligence solutions, including humanoid robots, quadruped robots, wheeled robots, and various solutions for education and industrial applications. The company also shared its practical achievements in embodied intelligence technology evolution, real-world scenario applications, and global ecosystem development. Industry-academia-research collaboration was one of the key topics. The conference officially launched the “Yuan Sheng Program” for Vietnam’s education and research sector, which will focus on curriculum development, joint laboratories, faculty training, student practice, and research projects to further integrate embodied intelligence robots into Vietnam’s education and research system.

As a key platform within Vietnam’s innovation ecosystem, NIC plays a leading role in promoting innovation and AI industry development. During the conference, NIC presented AGIBOT with the Innovation Partner Award and AGIBOT also recognized the first group of embodied AI ecosystem partners in Vietnam at a plaque presentation ceremony.

Abel Deng, President of AGIBOT Middle East & Asia-Pacific Region, stated: “Through the ‘Yuan Sheng Program’ and the RaaS (Robot as a Service) model, we aim to bring foundational AI large models, robotic bodies, and ecosystem capabilities into the Vietnamese market. Together with NIC and local partners, we will drive the validation and application of embodied intelligence across scenarios including education and research, retail services, cultural tourism and hospitality, and industrial manufacturing in Vietnam.”

In terms of industrial deployment, AGIBOT is deepening collaboration with local Vietnamese partner ECOLIV to jointly advance local operational capability building, including market expansion, project delivery, and after-sales service system development. The conference also announced the launch of the RaaS model. Leveraging the service network built by local ecosystem partners, enterprises, universities, and other users can deploy robotic applications in a more flexible manner based on actual scenarios, lowering initial deployment barriers and accelerating the validation and adoption of embodied intelligence technologies in real-world business scenarios.

Steve Chen, GM of ECOLIV, stated: “Vietnam possesses favorable conditions in manufacturing foundations, talent resources, innovation policies, and regional market connectivity, providing vast opportunities for the development of embodied intelligence technologies and industrial applications. In the future, ECOLIV will further deepen cooperation with NIC, Great Education, and relevant research institutions and universities, continuously advancing the deployment of embodied intelligence technologies in Vietnam across research innovation, talent development, industrial applications, and local ecosystem development.”

About AGIBOT

AGIBOT is a pioneer in the global general-purpose AI robotics industry, with its core technology focused on embodied AI. AGIBOT’s “Three Intelligences in One” architecture integrates Locomotion Intelligence, Interaction Intelligence, and Manipulation Intelligence into a unified embodied system. Its portfolio spans humanoid robots, quadrupeds, dexterous systems, and commercial cleaning solutions. In September 2026, AGIBOT announced that its 20,000th robot had rolled off the production line.

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/agibot-partners-with-vietnam-national-innovation-center-nic-to-advance-embodied-ai-industry-and-talent-ecosystem-302897081.html

SOURCE AGIBOT

New AI-enhanced solution helps identify promising drug formulations, compressing early clinical decision-making for new treatments

NOTTINGHAM, England, Oct. 2, 2026 /PRNewswire/ — Quotient Sciences, a global integrated CRDMO (contract research, development and manufacturing organization), and Acesion Pharma, a Copenhagen-based biotech company developing treatments for cardiac arrhythmia, today announced a new collaboration applying Quotient Sciences’ AI-enhanced formulation development solution within its Translational Pharmaceutics® platform.

The collaboration supports Acesion’s early-stage pipeline of small molecules targeted towards atrial fibrillation, the world’s most common sustained cardiac arrhythmia.

The collaboration reflects both companies’ shared commitment to advancing innovation in early drug development. Quotient Sciences’ AI-enhanced formulation development solution applies active machine learning (ML) with Bayesian optimization to help identify and prioritize the drug products most likely to succeed in the clinic, enabling partners such as Acesion to make faster, better-informed decisions earlier in development.

Atrial fibrillation: a growing global health challenge

The lifetime risk of developing atrial fibrillation is approximately one in three adults over age 55, making it one of the most common cardiovascular disorders associated with age.

Patients with atrial fibrillation face an approximately five-fold increased risk of stroke, making effective management critical for reducing serious complications. Atrial fibrillation impacts an estimated 50-60 million people globally.

AI-enhanced formulation development within Translational Pharmaceutics®

Quotient Sciences’ Translational Pharmaceutics® platform optimizes drug development by integrating a range of drug product formulation and clinical activities. It has been used by biotech and pharmaceutical companies globally as a proven method for advancing candidates through early development for more than 20 years.

Now enhanced with Quotient Sciences’ new AI-enhanced formulation development solution, Translational Pharmaceutics® allows development teams to analyze data and predict formulation performance earlier and more precisely, shortening development timelines further while supporting better-informed decisions. Early development activities can be focused on the drug product candidates with the highest chances of clinical success.

A collaboration built on innovation

Dr. Andrew Lewis, Chief Scientific Officer at Quotient Sciences, said: “This collaboration with Acesion Pharma reflects exactly what our AI-enhanced formulation development solution, combined with Translational Pharmaceutics®, is designed to deliver: helping our partners make better-informed, faster decisions about their drug product formulations. We’re proud to be working with Acesion on a shared commitment to innovation, and to support their pipeline in the field of atrial fibrillation.”

Dr. Elisabeth V. Carstensen, Vice President CMC, at Acesion Pharma said: “We are excited to, together with Quotient Sciences, explore how their AI-enhanced algorithms can help guide and accelerate oral formulation development for our small-molecule compounds. By helping to guide and accelerate development decisions, this approach has the potential to shorten timelines for clinical testing and increase the likelihood of achieving the desired product profile.”

About Acesion Pharma

Acesion Pharma is a privately held Danish biotech company developing novel treatments for atrial fibrillation (AF), the most common cardiac arrhythmia. Acesion aims to develop first-in-class SK channel inhibitors as a more efficacious, safe and tolerable treatment of AF. Existing drugs generally have a limited effect and are associated with risk of serious adverse events, and there is a considerable patient need for developing better and safer drugs. Acesion is the only company successfully progressing SK ion channel inhibitors into clinical trials and has demonstrated human proof-of-concept with its first-generation SK ion channel inhibitor AP30663 in pharmacological AF cardioversion (https://www.nature.com/articles/s41591-023-02679-9).

About Quotient Sciences

Quotient Sciences is an integrated CRDMO (contract research, development and manufacturing organization) providing services across the entire drug development and clinical pathway. Our flagship platform for drug development, Translational Pharmaceutics®, has been trusted by companies ranging from emerging biotechs to Fortune 50 pharmaceutical organizations for integrated drug product formulation, manufacturing and clinical testing. Enhanced with our new AI-driven formulation insights and backed by more than 20 years of experience, Translational Pharmaceutics® helps sponsors make better decisions earlier and advance towards proof-of-concept studies while reducing early development time, cost and risk. To learn more, visit quotientsciences.com.

Source: Quotient Sciences Global News

View original content:https://www.prnewswire.co.uk/news-releases/quotient-sciences-and-acesion-pharma-announce-collaboration-on-ai-enhanced-formulation-development-to-advance-atrial-fibrillation-pipeline-302897090.html